Literature DB >> 19576854

Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study.

Marie Vidailhet1, Jerome Yelnik, Christelle Lagrange, Valerie Fraix, David Grabli, Stephane Thobois, Pierre Burbaud, Marie-Laure Welter, Jin Xie-Brustolin, Maria-Clara Coelho Braga, Claire Ardouin, Virginie Czernecki, Hélène Klinger, Stephan Chabardes, Eric Seigneuret, Patrick Mertens, Emmanuel Cuny, Soledad Navarro, Philippe Cornu, Alim-Louis Benabid, Jean-Francois Le Bas, Didier Dormont, Marc Hermier, Kathy Dujardin, Serge Blond, Pierre Krystkowiak, Alain Destée, Eric Bardinet, Yves Agid, Paul Krack, Emmanuel Broussolle, Pierre Pollak.   

Abstract

BACKGROUND: Cerebral palsy (CP) with dystonia-choreoathetosis is a common cause of disability in children and in adults, and responds poorly to medical treatment. Bilateral pallidal deep brain stimulation (BP-DBS) of the globus pallidus internus (GPi) is an effective treatment for primary dystonia, but the effect of this reversible surgical procedure on dystonia-choreoathetosis CP, which is a subtype of secondary dystonia, is unknown. Our aim was to test the effectiveness of BP-DBS in adults with dystonia-choreoathetosis CP.
METHODS: We did a multicentre prospective pilot study of BP-DBS in 13 adults with dystonia-choreoathetosis CP who had no cognitive impairment, little spasticity, and only slight abnormalities of the basal ganglia on MRI. The primary endpoint was change in the severity of dystonia-choreoathetosis after 1 year of neurostimulation, as assessed with the Burke-Fahn-Marsden dystonia rating scale. The accuracy of surgical targeting to the GPi was assessed masked to the results of neurostimulation. Analysis was by intention to treat.
FINDINGS: The mean Burke-Fahn-Marsden dystonia rating scale movement score improved from 44.2 (SD 21.1) before surgery to 34.7 (21.9) at 1 year post-operatively (p=0.009; mean improvement 24.4 [21.1]%, 95% CI 11.6-37.1). Functional disability, pain, and mental health-related quality of life were significantly improved. There was no worsening of cognition or mood. Adverse events were related to stimulation (arrest of the stimulator in one patient, and an adjustment to the current intensity in four patients). The optimum therapeutic target was the posterolateroventral region of the GPi. Little improvement was seen when the neurostimulation diffused to adjacent structures (mainly to the globus pallidus externus [GPe]).
INTERPRETATION: Bilateral pallidal neurostimulation could be an effective treatment option for patients with dystonia-choreoathetosis CP. However, given the heterogeneity of motor outcomes and the small sample size, results should be interpreted with caution. The optimum placement of the leads seemed to be a crucial, but not exclusive, factor that could affect a good outcome. FUNDING: National PHRC; Cerebral Palsy Foundation: Fondation Motrice/APETREIMC; French INSERM Dystonia National Network; Medtronic.

Entities:  

Mesh:

Year:  2009        PMID: 19576854     DOI: 10.1016/S1474-4422(09)70151-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  52 in total

Review 1.  Mechanisms of deep brain stimulation.

Authors:  Todd M Herrington; Jennifer J Cheng; Emad N Eskandar
Journal:  J Neurophysiol       Date:  2015-10-28       Impact factor: 2.714

Review 2.  Dystonia rating scales: critique and recommendations.

Authors:  Alberto Albanese; Francesca Del Sorbo; Cynthia Comella; H A Jinnah; Jonathan W Mink; Bart Post; Marie Vidailhet; Jens Volkmann; Thomas T Warner; Albert F G Leentjens; Pablo Martinez-Martin; Glenn T Stebbins; Christopher G Goetz; Anette Schrag
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 3.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  Two-year outcomes of deep brain stimulation in adults with cerebral palsy.

Authors:  Ae Ryoung Kim; Jin Woo Chang; Won Seok Chang; Eun Sook Park; Sung-Rae Cho
Journal:  Ann Rehabil Med       Date:  2014-04-29

5.  Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia.

Authors:  Sara Meoni; Mateusz Zurowski; Andres M Lozano; Mojgan Hodaie; Yu-Yan Poon; Melanie Fallis; Valerie Voon; Elena Moro
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

6.  Globus pallidus deep brain stimulation for adult-onset axial dystonia.

Authors:  Aasef G Shaikh; Klaus Mewes; H A Jinnah; Mahlon R DeLong; Robert E Gross; Shirley Triche; Alan Freeman; Stewart A Factor
Journal:  Parkinsonism Relat Disord       Date:  2014-09-16       Impact factor: 4.891

7.  Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.

Authors:  L Timmermann; K A M Pauls; K Wieland; R Jech; G Kurlemann; N Sharma; S S Gill; C A Haenggeli; S J Hayflick; P Hogarth; K L Leenders; P Limousin; C J Malanga; E Moro; J L Ostrem; F J Revilla; P Santens; A Schnitzler; S Tisch; F Valldeoriola; J Vesper; J Volkmann; D Woitalla; S Peker
Journal:  Brain       Date:  2010-03-05       Impact factor: 13.501

Review 8.  Pathogenesis, neuroimaging and management in children with cerebral palsy born preterm.

Authors:  Alexander H Hoon; Andreia Vasconcellos Faria
Journal:  Dev Disabil Res Rev       Date:  2010

9.  Battery life following pallidal deep brain stimulation (DBS) in children and young people with severe primary and secondary dystonia.

Authors:  Daniel E Lumsden; Margaret Kaminska; Kylie Tustin; Hortensia Gimeno; Lesley Baker; Keyoumars Ashkan; Richard Selway; Jean-Pierre Lin
Journal:  Childs Nerv Syst       Date:  2012-03-18       Impact factor: 1.475

10.  Clinical course of patients with pantothenate kinase-associated neurodegeneration (PKAN) before and after DBS surgery.

Authors:  Marina Svetel; Aleksandra Tomić; Nataša Dragašević; Igor Petrović; Nikola Kresojević; Robert Jech; Dušan Urgošik; Isidora Banjac; Jelena Vitković; Ivana Novaković; Vladimir S Kostić
Journal:  J Neurol       Date:  2019-08-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.